NCT02611596

Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Walter Reed National Military Medical Center · Federal
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this investigation is to compare subjects at high risk for silent myocardial ischemia in the placebo group to subjects at high risk for silent myocardial ischemia in the ranolazine group to determine if ranolazine can be used as a treatment to decrease silent myocardial ischemia (SMI). Subjects at high risk for silent myocardial ischemia are defined in this protocol as diabetics with stable ischemic heart disease. This study will look at the impact ranolazine treatment has on biomarkers that have been shown to be highly associated with increased risk of morbidity and mortality in relation to SMI. If the hypothesis is correct, further studies can be conducted to determine if treatment with ranolazine has impact on long-term outcomes such as hospitalizations, myocardial infarction, congestive heart failure or sudden cardiac death.

Conditions

• Silent Myocardial Ischemia
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Ranolazine	24 weeks of the assigned medication
DRUG	Placebo	Placebo for 24 weeks

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-11-01
• Completion: 2019-11-01
• First posted: 2015-11-23
• Last updated: 2017-05-17